Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2016 Jun 22:5:F1000 Faculty Rev-1466.
doi: 10.12688/f1000research.8053.1. eCollection 2016.

Chemotherapy-induced peripheral neuropathy: an update on the current understanding

James Addington  1 , Miriam Freimer  1
Affiliations
Review

Chemotherapy-induced peripheral neuropathy: an update on the current understanding

James Addington et al. F1000Res. .

Abstract

Chemotherapy-induced peripheral neuropathy is a common side effect of selected chemotherapeutic agents. Previous work has suggested that patients often under report the symptoms of chemotherapy-induced peripheral neuropathy and physicians fail to recognize the presence of such symptoms in a timely fashion. The precise pathophysiology that underlies chemotherapy-induced peripheral neuropathy, in both the acute and the chronic phase, remains complex and appears to be medication specific. Recent work has begun to demonstrate and further clarify potential pathophysiological processes that predispose and, ultimately, lead to the development of chemotherapy-induced peripheral neuropathy. There is increasing evidence that the pathway to neuropathy varies with each agent. With a clearer understanding of how these agents affect the peripheral nervous system, more targeted treatments can be developed in order to optimize treatment and prevent long-term side effects.

Keywords: CIPN; Chemotherapy-induced peripheral neuropathy; Platinum agents; Taxanes; Vinca alkaloids; peripheral neuropathy.

PubMed Disclaimer

Conflict of interest statement

Competing interests: The authors declare that they have no competing interests.

No competing interests were disclosed.

References

    1. Chaudhry V, Rowinsky EK, Sartorius SE, et al. : Peripheral neuropathy from taxol and cisplatin combination chemotherapy: clinical and electrophysiological studies. Ann Neurol. 1994;35(3):304–11. 10.1002/ana.410350310 - DOI - PubMed
    1. Kautio A, Haanpää M, Kautiainen H, et al. : Burden of chemotherapy-induced neuropathy--a cross-sectional study. Support Care Cancer. 2011;19(12):1991–6. 10.1007/s00520-010-1043-2 - DOI - PubMed
    1. Smith EM, Cohen JA, Pett MA, et al. : The reliability and validity of a modified total neuropathy score-reduced and neuropathic pain severity items when used to measure chemotherapy-induced peripheral neuropathy in patients receiving taxanes and platinums. Cancer Nurs. 2010;33(3):173–83. 10.1097/NCC.0b013e3181c989a3 - DOI - PubMed
    1. Hausheer FH, Schilsky RL, Bain S, et al. : Diagnosis, management, and evaluation of chemotherapy-induced peripheral neuropathy. Semin Oncol. 2006;33(1):15–49. 10.1053/j.seminoncol.2005.12.010 - DOI - PubMed
    1. Shimozuma K, Ohashi Y, Takeuchi A, et al. : Taxane-induced peripheral neuropathy and health-related quality of life in postoperative breast cancer patients undergoing adjuvant chemotherapy: N-SAS BC 02, a randomized clinical trial. Support Care Cancer. 2012;20(12):3355–64. 10.1007/s00520-012-1492-x - DOI - PubMed